This bill reauthorizes federal programs focused on preventing and responding to tick-borne diseases through 2026-2030, extending existing efforts beyond their previous expiration. It updates the National Strategy for Vector-Borne Diseases to emphasize identifying, reporting, preventing, and responding to these illnesses. The bill modifies two sections of the Public Health Service Act to continue funding for health departments working on vector-borne disease control. It directly affects public health programs and state/local health departments managing tick-borne disease prevention and response.
The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
HR 1266, the Combating Illicit Xylazine Act, adds xylazine - a veterinary sedative increasingly found in illicit drug mixtures - to Schedule III of the Controlled Substances Act, regulating its use and trafficking. It directly affects veterinarians, animal owners, and manufacturers by allowing xylazine to be legally dispensed for animal use under specific veterinary prescriptions, while prohibiting non-veterinary human use. The bill includes transition periods (60 days for practitioners, 1 year for labeling) to ease compliance for manufacturers and practitioners, and requires the DEA and FDA to expedite necessary applications. It also mandates two congressional reports on xylazine's illicit use and trafficking patterns, and directs the Sentencing Commission to review penalties for offenses involving xylazine.
HR 2913, the Ukraine Support Act, provides comprehensive U.S. support for Ukraine in response to Russia's invasion. The bill authorizes security assistance including lend-lease authority for military equipment, establishes a Ukraine Reconstruction Trust Fund for economic recovery, and imposes new sanctions targeting Russian financial institutions, oil companies, and government officials. It also includes provisions to counter Russian disinformation, support Radio Free Europe, and address the kidnapping of Ukrainian children. The legislation directly affects U.S. foreign policy, Ukraine's defense capabilities, and Russia's access to international financial systems. The act aims to strengthen Ukraine's sovereignty while holding Russia accountable for its actions.
The Save MEDICARE Act of 2026 aims to improve the Medicare Advantage program by starting in 2028 with several changes to how health plans are paid and monitored. It requires the government to exclude diagnoses from chart reviews when calculating payments to prevent plans from inflating costs based on questionable data. The bill also speeds up audits and appeals to ensure faster resolution of coding disputes and introduces a new penalty system to recover overpayments from plans. Additionally, the law allows states to enforce Medicare rules within their borders and bans financial incentives for doctors based on how they code patient records. Finally, it establishes a mechanism for the Department of Veterans Affairs to recover costs when Medicare Advantage plans cover care that should have been paid for by the VA.
This resolution designates July 2026 as "Plastic Pollution Action Month" to raise awareness about the environmental and health risks associated with plastic waste. The bill recognizes that plastic pollution harms marine life and human health, citing statistics on ocean contamination and the presence of microplastics in the human body. It encourages all individuals in the United States to participate in activities aimed at reducing plastic use and cleaning up litter during the designated month. The measure does not create new laws or regulations but serves to highlight the issue and promote voluntary action.
This resolution honors the life and legacy of the late Senator Lindsey Olin Graham from South Carolina. It formally acknowledges his extensive career in the military, state government, and Congress, noting his service as a Senator and his roles as Chairman of the Judiciary and Budget committees. The Senate expresses its sorrow over his death and requests that this tribute be shared with the House of Representatives and Graham's family.
This bill establishes a comprehensive sanctions framework targeting the Russian government and its affiliated entities in response to ongoing military actions. It authorizes the President to block assets, revoke visas, and prohibit financial transactions for Russian officials, military leaders, and foreign persons supporting Russia's defense industry or undermining Ukraine. The legislation also bans U.S. investments in Russian energy sectors, prohibits the purchase of Russian sovereign debt, and imposes high tariffs on Russian imports while restricting crude oil purchases by specific foreign nations. Additionally, the bill prevents Russian companies from listing on U.S. stock exchanges and includes mechanisms for terminating sanctions only if Russia signs a peace agreement accepted by Ukraine and ceases hostilities.
The Disclosure of Tax Havens and Offshoring Act requires large multinational companies to publicly report their financial performance in every country where they operate. Specifically, it mandates that these firms submit detailed reports to the Securities and Exchange Commission showing revenues, profits, taxes paid, and employee counts for each jurisdiction. The law also requires this data to be provided in a machine-readable format and made available online for public access. Companies must follow specific rules for defining which entities and locations are included in these reports, with the Commission expected to issue final regulations within a year of the bill's enactment.
The Curtailing Executive Overcompensation (CEO) Act imposes a new excise tax on large companies where the highest-paid CEO earns significantly more than the median worker. This tax applies to employers with over $100 million in annual revenue and over $10 million in wages, charging a fee equal to the lesser of 1% of the pay gap or 1% of the company's gross receipts. The law defines the pay gap as the difference between the CEO's average compensation and 50 times the median wage of all employees earning at least $5,000, with thresholds adjusted for inflation after 2027. Companies found to be manipulating their workforce to avoid the tax could face joint liability, and the IRS will issue regulations to prevent such avoidance.
Orlin's Law requires immigration officials to identify detained parents and prioritize family unity by limiting detention when possible. The bill mandates that parents be allowed to make free calls and visits with their children, participate in family court proceedings, and access necessary documents to care for their dependents. It also establishes a new office within U.S. Immigration and Customs Enforcement to coordinate these protections and provides for community-based alternatives to detention. Additionally, the law creates a presumption that parental rights remain intact even if a child is separated from a detained parent and outlines specific steps to facilitate reunification upon removal.
The TRUTH in Coverage Act of 2026 requires group health plans and health insurance issuers that cover gender-affirming procedures to also cover medical services intended to treat physical and psychological complications resulting from those procedures. This mandate applies regardless of whether the original gender-affirming treatment was covered by the plan and ensures that any required follow-up care faces the same cost-sharing rules and limitations as standard medical benefits. The bill defines "sex-rejecting procedures" broadly to include hormone therapy, surgeries, and puberty blockers, while explicitly excluding treatments for intersex conditions, life-threatening emergencies, and standard puberty suppression for early puberty. These provisions would take effect for plan years beginning on or after January 1, 2027, affecting individuals with access to employer-sponsored or individual health insurance.
